tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

YMAB Stock Latest News

Y-mAbs Therapeutics announces new data on naxitamab, GD2-SADA
The FlyY-mAbs Therapeutics announces new data on naxitamab, GD2-SADA
14d ago
YMAB
Y-mAbs Presents Neuroblastoma Research on Naxitamab and SADA PRIT Technology Platform at AACR Special Conference on Advances in Pediatric Cancer Research
PremiumPress Releases
Y-mAbs Presents Neuroblastoma Research on Naxitamab and SADA PRIT Technology Platform at AACR Special Conference on Advances in Pediatric Cancer Research
14d ago
YMAB
Y-mAbs to Participate in Upcoming Investor Conferences in September
PremiumPress Releases
Y-mAbs to Participate in Upcoming Investor Conferences in September
17d ago
YMAB
Cisco, Nike upgrades among today’s top calls on Wall Street
PremiumThe Fly
Cisco, Nike upgrades among today’s top calls on Wall Street
1M ago
EL
JD
Cantor starts Y-mAbs with Overweight on pivot to radiopharmaceuticals
PremiumThe Fly
Cantor starts Y-mAbs with Overweight on pivot to radiopharmaceuticals
1M ago
YMAB
Y-mAbs Therapeutics initiated with an Overweight at Cantor Fitzgerald
PremiumThe FlyY-mAbs Therapeutics initiated with an Overweight at Cantor Fitzgerald
1M ago
YMAB
Y-mAbs Therapeutics price target lowered to $11 from $12 at Morgan Stanley
Premium
The Fly
Y-mAbs Therapeutics price target lowered to $11 from $12 at Morgan Stanley
1M ago
YMAB
Y-mAbs Therapeutics price target lowered to $25 from $26 at BMO Capital
Premium
The Fly
Y-mAbs Therapeutics price target lowered to $25 from $26 at BMO Capital
1M ago
YMAB
Morning Movers: KeyCorp surges following Scotiabank taking stake
PremiumThe Fly
Morning Movers: KeyCorp surges following Scotiabank taking stake
1M ago
HE
CYD
Y-mAbs Therapeutics sees annual cash burn $15M-$20M
PremiumThe Fly
Y-mAbs Therapeutics sees annual cash burn $15M-$20M
1M ago
YMAB
Y-mAbs Therapeutics sees FY24 revenue $87M-$95M, consensus $95.18M
PremiumThe Fly
Y-mAbs Therapeutics sees FY24 revenue $87M-$95M, consensus $95.18M
1M ago
YMAB
Y-mAbs Therapeutics reports Q2 EPS (21c), consensus (13c)
PremiumThe Fly
Y-mAbs Therapeutics reports Q2 EPS (21c), consensus (13c)
1M ago
YMAB
YMAB Upcoming Earnings Report: What to Expect?
PremiumPre-EarningsYMAB Upcoming Earnings Report: What to Expect?
1M ago
YMAB
Y-mAbs to Participate in Upcoming Investor Conferences in August
Premium
Press Releases
Y-mAbs to Participate in Upcoming Investor Conferences in August
1M ago
YMAB
Y-mAbs Announces Second Quarter 2024 Conference Call and Webcast
Premium
Press Releases
Y-mAbs Announces Second Quarter 2024 Conference Call and Webcast
2M ago
YMAB
Y-mAbs Therapeutics Finalizes CFO Transition and Advisory Deal
PremiumCompany Announcements
Y-mAbs Therapeutics Finalizes CFO Transition and Advisory Deal
2M ago
8K
YMAB
Y-mAbs Therapeutics initiated with a Buy at JonesResearch
PremiumThe Fly
Y-mAbs Therapeutics initiated with a Buy at JonesResearch
2M ago
YMAB
Y-Mabs Therapeutics Welcomes New CFO Amid Strategic Shift
PremiumCompany Announcements
Y-Mabs Therapeutics Welcomes New CFO Amid Strategic Shift
3M ago
8K
YMAB
Y-mAbs Therapeutics appoints Peter Pfreundschuh as CFO
PremiumThe Fly
Y-mAbs Therapeutics appoints Peter Pfreundschuh as CFO
3M ago
YMAB
Y-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial Officer
PremiumPress ReleasesY-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial Officer
3M ago
YMAB
Y-mAbs Therapeutics initiated with a Buy at Truist
Premium
The Fly
Y-mAbs Therapeutics initiated with a Buy at Truist
3M ago
YMAB
Y-mAbs Therapeutics announces preclinical GD2-SADA to be presented at SNMMI
Premium
The Fly
Y-mAbs Therapeutics announces preclinical GD2-SADA to be presented at SNMMI
3M ago
YMAB

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >